Cronyxin Injection, 5% w/v Solution for Injection

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Flunixin

Available from:

Bimeda Animal Health Limited

ATC code:

QM01AG90

INN (International Name):

Flunixin

Pharmaceutical form:

Solution for injection

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cattle, Horses

Therapeutic area:

Anti Inflammatory NSAID

Authorization status:

Authorized

Authorization date:

1996-03-14

Summary of Product characteristics

Revised: June 2020
AN: 00138/2020
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Cronyxin Injection, 5% w/v Solution for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
EACH ML CONTAINS:
ACTIVE SUBSTANCE(S):
mg
Flunixin
50
(as Flunixin Meglumine)
EXCIPIENT(S):
Phenol (as preservative)
5
Sodium Formaldehyde Sulfoxylate (as antioxidant)
2.2
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for Injection.
Clear, colourless to light yellow solution, free of foreign matter.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle and horses
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
CATTLE
For
the
control
of
acute
inflammation
associated
with
respiratory disease. It has also been shown to have some
benefit
in
the
treatment
of
experimental
acute
bovine
pulmonary emphysema (Fog fever).
Cronyxin injection may be used as adjunctive therapy in the
treatment of acute mastitis.
HORSES
For the alleviation of inflammation and pain associated with
musculoskeletal disorders.
It is also indicated for the alleviation of visceral pain associated
with
colic.
Revised: June 2020
AN: 00138/2020
Page 2 of 6
4.3
CONTRA-INDICATIONS
Do not exceed the stated dose or duration of treatment.
Use is contra-indicated in animals suffering from cardiac, hepatic or
renal
disease,
where
there
is
the
possibility
of
gastro-intestinal
ulceration or bleeding, where this is evidence of blood dyscrasia or
hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of
each other.
Avoid intra-arterial injection.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as
there is a potential risk of increased renal toxicity.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
NSAIDs
can
cause
inhibition
of
phagocytosis
and
hence
in
the
treatment
of
inflammatory
conditions
associated
with
bacterial
infections,
appropriate
concurrent
antimicrobial
therapy
should
be
instigated.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in